Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) – Investment analysts at Leerink Swann lifted their Q3 2017 earnings per share (EPS) estimates for Alder BioPharmaceuticals in a research note issued on Wednesday. Leerink Swann analyst P. Matteis now forecasts that the biopharmaceutical company will post earnings per share of ($1.06) for the quarter, up from their prior forecast of ($1.33). Leerink Swann has a “Outperform” rating and a $32.00 price target on the stock. Leerink Swann also issued estimates for Alder BioPharmaceuticals’ Q4 2017 earnings at ($1.11) EPS, FY2017 earnings at ($5.45) EPS and FY2018 earnings at ($3.30) EPS.

Other equities analysts have also issued reports about the company. Zacks Investment Research raised Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a report on Tuesday, July 11th. Aegis reaffirmed a “buy” rating and set a $41.00 target price on shares of Alder BioPharmaceuticals in a report on Wednesday, July 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $43.00 target price on shares of Alder BioPharmaceuticals in a report on Monday, April 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Alder BioPharmaceuticals in a report on Friday, June 9th. Finally, Credit Suisse Group lowered Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $30.00 to $17.00 in a report on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $32.92.

COPYRIGHT VIOLATION WARNING: “Q3 2017 EPS Estimates for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Boosted by Leerink Swann” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/11/q3-2017-eps-estimates-for-alder-biopharmaceuticals-inc-nasdaqaldr-boosted-by-leerink-swann.html.

Alder BioPharmaceuticals (ALDR) opened at 8.85 on Friday. Alder BioPharmaceuticals has a 1-year low of $8.80 and a 1-year high of $36.48. The company’s 50-day moving average price is $11.85 and its 200-day moving average price is $18.30. The stock’s market cap is $599.26 million.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, beating analysts’ consensus estimates of ($1.67) by $0.19. The business had revenue of $0.68 million during the quarter. During the same quarter in the prior year, the firm posted ($0.79) EPS. The business’s revenue was up 518.2% on a year-over-year basis.

In other Alder BioPharmaceuticals news, Director Stephen M. Dow acquired 25,000 shares of Alder BioPharmaceuticals stock in a transaction dated Tuesday, July 18th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $250,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.60% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Legal & General Group Plc increased its position in shares of Alder BioPharmaceuticals by 2.6% in the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 400 shares in the last quarter. Teachers Advisors LLC increased its position in shares of Alder BioPharmaceuticals by 1.5% in the fourth quarter. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company’s stock valued at $1,598,000 after buying an additional 1,171 shares in the last quarter. Baird Financial Group Inc. increased its position in shares of Alder BioPharmaceuticals by 7.9% in the first quarter. Baird Financial Group Inc. now owns 18,441 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 1,349 shares in the last quarter. Swiss National Bank increased its position in shares of Alder BioPharmaceuticals by 2.6% in the first quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock valued at $1,380,000 after buying an additional 1,700 shares in the last quarter. Finally, American International Group Inc. increased its position in shares of Alder BioPharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 28,849 shares of the biopharmaceutical company’s stock valued at $600,000 after buying an additional 1,910 shares in the last quarter. Institutional investors and hedge funds own 82.44% of the company’s stock.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Earnings History and Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.